S-W. Kim - Dept Oncol, Asan Med Ctr | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)

C.K. Lee,Y. Cheng, K. Laktionov,S-W. Kim,T. Kato, J. Wang, P. Mitchell, V. Bermudez, S. Kuyama, J.Y. Tan Chun Bing, J.E. Cundom, G.D.J. Pinto,

ESMO Open (2024)

引用0浏览0引用

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC

H A Yu, C Baik,D-W Kim, M L Johnson, H Hayashi, M Nishio,J C-H Yang, W-C Su, K A Gold, M Koczywas, E F Smit, C E Steuer,

Annals of oncology : official journal of the European Society for Medical Oncology (2024)

引用0浏览0WOS引用

7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC

L. Paz-Ares, R. Veillon, M. Majem, C. Zhou, K-J. Tang,S-W. Kim, G. Richardson, N. Girard, R.E. Sanborn, A.S. Mansfield, K. Park, J. Sermon,

ESMO Open (2024)

引用0浏览0引用

First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

D. Planchard, A. Poltoratskiy,S-W. Kim,T. M. Kim, N. Yanagitani, H. Kagamu,P-H. Feng, B. Hughes,T-Y. Yang,J. C-H. Yang, C. K. Lee, N. Karaseva,

ANNALS OF ONCOLOGY (2023): S1692-S1693

引用0浏览0引用

PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)

P. Janne, D. Planchard,Y. Cheng,J.C.-H. Yang, N. Yanagitani,S.-W. Kim, S. Sugawara,Y. Yu, Y. Fan, S.L. Geater, K. Laktionov, C.K. Lee,

Journal of Thoracic Oncologyno. 11 (2023): S36-S37

引用0浏览0引用

Repotrectinib in patients (pts) from Asia and China with ROS1 fusion- positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial

S. Lu, X. Hu,S-W. Kim, K. Goto, N. Yang, R. A. Soo, J. Fang, W. Yao, K. H. Lee,D. W-T. Lim,T. Kato, M. Tamiya,

ANNALS OF ONCOLOGY（2023）

引用0浏览0引用

LBA53 ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

Z. Piotrowska,M-J. Ahn, Y.K. Pang, S.H. How,S-W. Kim, P.J. Voon, D.L. Cortinovis,J. De Castro Carpeno, M. Tiseo,D. Rodriguez Abreu,S.S. Ramalingam, J. Li,

Annals of Oncology (2022): S1420-S1421

引用0浏览0引用

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

M. Tsuboi,Y-L. Wu,C. Grohe,T. John,M. Majem Tarruella, J. Wang,T. Kato,J.W. Goldman,S-W. Kim,C-J. Yu,H. Vinh Vu,G. Mukhametshina,

Annals of Oncology (2022)

引用5浏览0引用

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

M. Tsuboi,Y-L. Wu,C. Grohe,T. John,M. Majem Tarruella, J. Wang,T. Kato,J.W. Goldman,S-W. Kim,C-J. Yu,H. Vinh Vu,G. Mukhametshina,

Annals of Oncology (2022): S1413-S1414

引用0浏览0引用

296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

Y-L. Wu,M. Tsuboi, C. Grohe,T. John,M. Majem Tarruella, J. Wang, T. Kato, J.W. Goldman,S-W. Kim,C-J. Yu,H. Vinh Vu, G. Mukhametshina,

ANNALS OF ONCOLOGY（2022）

引用21浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn